Selected research
Industry Research
Efavirenz Industry Research Report 2026
Market perspective
The global Efavirenz market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Efavirenz is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Efavirenz is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Efavirenz include Teva, Mylan, Macleods Pharmaceuticals, Hetero, Cipla, Bristol-Myers Squibb and Aurobindo Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Efavirenz market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Efavirenz Market by Company
Teva
Mylan
Macleods Pharmaceuticals
Hetero
Cipla
Bristol-Myers Squibb
Aurobindo Pharma
Efavirenz Segment by Type
Two-drug combination
Three-drug combination
Efavirenz Segment by Application
Adults
Children
Efavirenz Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Efavirenz market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Efavirenz and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Efavirenz.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Efavirenz manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Efavirenz by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Efavirenz in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Two-drug combination
- Three-drug combination
Applications
- Adults
- Children
Companies covered
- Teva
- Mylan
- Macleods Pharmaceuticals
- Hetero
- Cipla
- Bristol-Myers Squibb
- Aurobindo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Efavirenz Market Size (2021-2032)
- 2.2.2 Global Efavirenz Sales (2021-2032)
- 2.2.3 Global Efavirenz Market Average Price (2021-2032)
- 2.3 Efavirenz by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Two-drug combination
- 2.3.3 Three-drug combination
- 2.4 Efavirenz by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Efavirenz Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Efavirenz Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Efavirenz Revenue of Manufacturers (2021-2026)
- 3.4 Global Efavirenz Average Price by Manufacturers (2021-2026)
- 3.5 Global Efavirenz Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Efavirenz, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Efavirenz, Product Type & Application
- 3.8 Global Manufacturers of Efavirenz, Established Date
- 3.9 Global Efavirenz Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Efavirenz Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Efavirenz Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Macleods Pharmaceuticals
- 4.3.1 Macleods Pharmaceuticals Company Information
- 4.3.2 Macleods Pharmaceuticals Business Overview
- 4.3.3 Macleods Pharmaceuticals Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Macleods Pharmaceuticals Efavirenz Product Portfolio
- 4.3.5 Macleods Pharmaceuticals Recent Developments
- 4.4 Hetero
- 4.4.1 Hetero Company Information
- 4.4.2 Hetero Business Overview
- 4.4.3 Hetero Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hetero Efavirenz Product Portfolio
- 4.4.5 Hetero Recent Developments
- 4.5 Cipla
- 4.5.1 Cipla Company Information
- 4.5.2 Cipla Business Overview
- 4.5.3 Cipla Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Cipla Efavirenz Product Portfolio
- 4.5.5 Cipla Recent Developments
- 4.6 Bristol-Myers Squibb
- 4.6.1 Bristol-Myers Squibb Company Information
- 4.6.2 Bristol-Myers Squibb Business Overview
- 4.6.3 Bristol-Myers Squibb Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bristol-Myers Squibb Efavirenz Product Portfolio
- 4.6.5 Bristol-Myers Squibb Recent Developments
- 4.7 Aurobindo Pharma
- 4.7.1 Aurobindo Pharma Company Information
- 4.7.2 Aurobindo Pharma Business Overview
- 4.7.3 Aurobindo Pharma Efavirenz Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Aurobindo Pharma Efavirenz Product Portfolio
- 4.7.5 Aurobindo Pharma Recent Developments
5 Global Efavirenz Market Scenario by Region
- 5.1 Global Efavirenz Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Efavirenz Sales by Region: 2021-2032
- 5.2.1 Global Efavirenz Sales by Region: 2021-2026
- 5.2.2 Global Efavirenz Sales by Region: 2027-2032
- 5.3 Global Efavirenz Revenue by Region: 2021-2032
- 5.3.1 Global Efavirenz Revenue by Region: 2021-2026
- 5.3.2 Global Efavirenz Revenue by Region: 2027-2032
- 5.4 North America Efavirenz Market Facts & Figures by Country
- 5.4.1 North America Efavirenz Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Efavirenz Sales by Country (2021-2032)
- 5.4.3 North America Efavirenz Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Efavirenz Market Facts & Figures by Country
- 5.5.1 Europe Efavirenz Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Efavirenz Sales by Country (2021-2032)
- 5.5.3 Europe Efavirenz Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Efavirenz Market Facts & Figures by Country
- 5.6.1 Asia Pacific Efavirenz Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Efavirenz Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Efavirenz Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Efavirenz Market Facts & Figures by Country
- 5.7.1 South America Efavirenz Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Efavirenz Sales by Country (2021-2032)
- 5.7.3 South America Efavirenz Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Efavirenz Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Efavirenz Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Efavirenz Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Efavirenz Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Efavirenz Sales by Type (2021-2032)
- 6.1.1 Global Efavirenz Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Efavirenz Sales Market Share by Type (2021-2032)
- 6.2 Global Efavirenz Revenue by Type (2021-2032)
- 6.2.1 Global Efavirenz Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Efavirenz Revenue Market Share by Type (2021-2032)
- 6.3 Global Efavirenz Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Efavirenz Sales by Application (2021-2032)
- 7.1.1 Global Efavirenz Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Efavirenz Sales Market Share by Application (2021-2032)
- 7.2 Global Efavirenz Revenue by Application (2021-2032)
- 7.2.1 Global Efavirenz Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Efavirenz Revenue Market Share by Application (2021-2032)
- 7.3 Global Efavirenz Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Efavirenz Value Chain Analysis
- 8.1.1 Efavirenz Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Efavirenz Production Mode & Process
- 8.2 Efavirenz Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Efavirenz Distributors
- 8.2.3 Efavirenz Customers
9 Global Efavirenz Analyzing Market Dynamics
- 9.1 Efavirenz Industry Trends
- 9.2 Efavirenz Industry Drivers
- 9.3 Efavirenz Industry Opportunities and Challenges
- 9.4 Efavirenz Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst